SWOG S0023: What meets the eye may be only half the truth

被引：4

作者：

Bhutani, Manisha ^{[1
]}

Pathak, Ashutosh K. ^{[1
]}

Mao, Li ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 29期

关键词：

D O I：

10.1200/JCO.2008.18.4218

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：4848 / 4849

页数：2

相关论文

共 8 条

[1]

Influence of unrecognized molecular heterogeneity on randomized clinical trials [J].

Betensky, RA ;

Louis, DN ;

Cairncross, JG .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2495-2499

[2]

A pilot study of sequential therapy with gefitinib following chemotherapy in advanced non-small cell lung cancer (NSCLC) [J].

Bhutani, M ;

Pathak, A ;

Guleria, R ;

Mohan, A ;

Kochupillai, V .

LUNG CANCER, 2005, 49 :S236-S237

[3]

Does gefitinib shorten lung cancer survival? Chaos Redux [J].

Keedy, Vicki L. ;

Arteaga, Carlos L. ;

Johnson, David H. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2428-2430

[4]

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 [J].

Kelly, Karen ;

Chansky, Kari ;

Gaspar, Laurie E. ;

Albain, Kathy S. ;

Jett, James ;

Ung, Yee C. ;

Lau, Derick H. M. ;

Crowley, John J. ;

Gandara, David R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2450-2456

[5]

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[6]

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations [J].

Sequist, Lecia V. ;

Martins, Renato G. ;

Spigel, David ;

Grunberg, Steven M. ;

Spira, Alexander ;

Jaenne, Pasi A. ;

Joshi, Victoria A. ;

McCollum, David ;

Evans, Tracey L. ;

Muzikansky, Alona ;

Kuhlmann, Georgiana L. ;

Han, Moon ;

Goldberg, Jonathan S. ;

Settleman, Jeffrey ;

Iafrate, A. John ;

Engelman, Jeffrey A. ;

Haber, Daniel A. ;

Johnson, Bruce E. ;

Lynch, Thomas J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2442-2449

[7]

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) [J].

Thatcher, N ;

Chang, A ;

Parikh, P ;

Pereira, JR ;

Ciuleanu, T ;

von Pawel, J ;

Thongprasert, S ;

Tan, EH ;

Pemberton, K ;

Archer, V ;

Carroll, K .

LANCET, 2005, 366 (9496) :1527-1537

[8]

Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes [J].

Wheatley-Price, Paul ;

Shepherd, Frances A. .

CURRENT OPINION IN ONCOLOGY, 2008, 20 (02) :162-175